Showing results (151-160 of 293) with videos related to

Sort By:
Pageof 30
Diabetes Care|September 7, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2017
NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in miceRyan E Tomlinson, Zhi Li, Zhu Li, et al.
Diabetes Care|January 29, 2005
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetesHans U Janka, Gerd Plewe, Matthew C Riddle, et al.
Journal of the National Cancer Institute|December 20, 2015
Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer MetastasisDiane S Abou, David Ulmert, Michele Doucet, et al.
Diabetes, Obesity & Metabolism|June 13, 2014
Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised studyW H Polonsky, S Thompson, W Wei, et al.
Diabetes Care|June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Vox Sanguinis|December 12, 2007
Severe fetomaternal alloimmune thrombocytopenia due to anti-human platelet antigen (HPA)-1a in a mother with a rare and silenced ITGB3*0101 (GPIIIa) alleleG A Smith, A Rankin, C Riddle, et al.
Patient Education and Counseling|January 10, 1998
Long-term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical officeR E Glasgow, P A La Chance, D J Toobert, et al.
Diabetes, Obesity & Metabolism|May 13, 2022
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trialEdward Franek, Hertzel C Gerstein, Matthew C Riddle, et al.
Nature Methods|February 11, 2022
VascuViz: a multimodality and multiscale imaging and visualization pipeline for vascular systems biologyAkanksha Bhargava, Benjamin Monteagudo, Priyanka Kushwaha, et al.
Pageof 30